Stockscreener 앱 받기
7.34
11.21%
0.74
시간 외 거래:
7.49
0.15
+2.04%
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology Shares Rise After CEO Buys Company Shares - MarketScreener
Why Kura Oncology (KURA.O) Spiked 14% on a Quiet Day — A Technical Deep Dive - AInvest
Kura Oncology Surges 13.18%—What's Really Behind the Intraday Move? - AInvest
Kura Oncology Inc. stock chart pattern explainedTrade Volume Summary & High Accuracy Investment Signals - Newser
How hedge fund analytics apply to Kura Oncology Inc. stock2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser
What does recent volatility data suggest for Kura Oncology Inc.Gap Down & AI Driven Stock Reports - Newser
Price Consolidation Hints at Upcoming Move in Kura Oncology Inc.2025 Fundamental Recap & Weekly Setup with ROI Potential - sundaytimes.kr
JMP Securities Lowers Kura Oncology Price Target to $24, Maintains Market Outperform Rating - AInvest
Analysts Weigh In on 10x Genomics, Kura Oncology and Insulet: Buy or Hold? - AInvest
Is Kura Oncology Inc. stock entering bullish territoryMarket Risk Report & Smart Allocation Stock Tips - Newser
JMP Securities Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Kura Oncology Inc. stock attracts strong analyst attentionDouble in 10 Days Stock Ideas - newsyoung.net
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Nigeria
Wedbush Has Bearish Forecast for Kura Oncology Q1 Earnings - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
JMP Securities Maintains Market Outperform on Kura Oncology with New PT of $24 - AInvest
Kura Oncology stock price target lowered to $24 at Citizens JMP - Investing.com Canada
What candlestick patterns are forming on Kura Oncology Inc.Free Pattern Detection for Entry Confirmation - Newser
Kura Oncology price target lowered to $27 from $29 at BofA - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
What makes Kura Oncology Inc. stock price move sharplyFree Daily Chart Pattern Stock Forecast - Newser
Kura Oncology Reports Q2 2025 Earnings: Key Takeaways - AInvest
Order flow analysis tools used on Kura Oncology Inc.Equity Performance Forecast Based on AI Models - Newser
Chart based analysis of Kura Oncology Inc. trendsFree Short Term Buy Zone Stock Alerts - Newser
Candlestick Reversal Detected on Kura Oncology Inc.’s ChartStrong Buy With Technical Confidence Supported - beatles.ru
How to escape a deep drawdown in Kura Oncology Inc.Market Downturn Defense Strategy Analysis - Newser
Kura Oncology shares fall 5.12% intraday despite FDA Priority Review of ziftomenib NDA. - AInvest
Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating - TipRanks
Earnings call transcript: Kura Oncology Q2 2025 shows revenue miss, EPS below forecast - Investing.com Nigeria
Kura Oncology: Q2 Earnings Snapshot - Connecticut Post
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses By GuruFocus - Investing.com Canada
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strat - GuruFocus
Kura Oncology Advances Cancer Drug Pipeline with FDA Review - TipRanks
Published on: 2025-08-07 23:14:29 - Newser
Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
Kura Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kura Oncology Reports Second Quarter 2025 Financial Results | KU - GuruFocus
Kura Oncology Inc earnings missed by $0.34, revenue fell short of estimates - Investing.com South Africa
Q2 2025 Kura Oncology Inc Earnings Call Transcript - GuruFocus
Kura Oncology Reports Second Quarter 2025 Financial Results - Yahoo Finance
Dimensional US Core Equity 2 ETF (DFAC) Implied Analyst Target Price: $41.37, With 12.92% Upside Expected. - AInvest
Kura Oncology Grants Inducement Stock Options to New Employees Under Nasdaq Listing Rule - AInvest
Kura Oncology KURA Q2 2025 Earnings Preview Upside Potential on Robust Revenue Forecast - AInvest
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology grants stock options to new employees under inducement plan. - AInvest
Cancer Drug Developer Kura Oncology Makes Major Hiring Push: 35 New Scientists Join Precision Medicine Team - Stock Titan
How strong is Kura Oncology Inc. company’s balance sheetUnlock powerful investment tools for free - Jammu Links News
What are the technical indicators suggesting about Kura Oncology Inc.Unlock powerful trading signals and alerts - Jammu Links News
What markets is Kura Oncology Inc. expanding into Is GURE stock a good long term investment optionTremendous gains - Jammu Links News
What institutional investors are buying Kura Oncology Inc. stockTake advantage of unprecedented market momentum - Jammu Links News
What drives Kura Oncology Inc. stock priceUnmatched profit potential - Jammu Links News
What are analysts’ price targets for Kura Oncology Inc. in the next 12 monthsDiscover stocks with explosive upside potential - Jammu Links News
Why is Kura Oncology Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Using flow based indicators on Kura Oncology Inc.Asset Allocation Summary With Future Outlook - Newser
What are the latest earnings results for Kura Oncology Inc.Fast-track wealth growth - Jammu Links News
Kura Oncology targets 2028 MRD-negative CR results for frontline AML trials - MSN
0.41%
0.88%
자본화:
|
볼륨(24시간):